Rapidly progressive puberty is a distinct clinical problem from classic precocious puberty. Affected girls begin puberty at a roughly normal age, but then accelerate through the Tanner stages at an alarming pace, with bone age racing ahead of chronological age. Because estrogen drives the fusion of the growth plates, this acceleration locks in a compromised predicted adult height. Gonadotropin-releasing hormone agonists, or GnRHa, are the standard tool for halting central precocious puberty, and Chinese consensus guidelines now allow their use in rapidly progressive puberty when the height prognosis is severely threatened. Yet clinicians have noticed that some girls on GnRHa monotherapy continue to show bone age advancement, hinting that their estrogen supply does not come from the ovaries alone.

That observation points to aromatase, the CYP19A1 enzyme that converts adrenal-derived androgen precursors into estrogens in peripheral tissues. Block this enzyme with a drug like letrozole, the reasoning goes, and you shut down the second estrogen source, slowing growth plate fusion further. Third-generation aromatase inhibitors such as letrozole and anastrozole are already used for short stature, mainly in boys, where they can raise predicted adult height. In girls, however, their use has been rare—largely confined to McCune-Albright syndrome—because of a central concern: if aromatase is blocked while androgens keep flowing, androgens might accumulate and trigger virilizing effects such as hirsutism and acne.

The new study, led by researchers at the Second Hospital of Hebei Medical University in Shijiazhuang, was designed to test that concern with unprecedented hormonal resolution. The team enrolled 28 girls with advanced bone age between July 2025 and April 2026. Thirteen girls, designated Group A, started combination therapy—GnRHa injections every four weeks plus daily oral letrozole at 1.25 milligrams—from the outset. The other fifteen, Group B, were already on GnRHa monotherapy and were offered letrozole as an add-on. Group assignment reflected the timing of letrozole introduction in routine clinical care rather than systematic allocation, and the authors acknowledge this was not a randomized design.

The methodological centerpiece was liquid chromatography–tandem mass spectrometry, or LC-MS/MS, a technique that detects and quantifies steroid hormones with far greater sensitivity and specificity than traditional immunoassays. Blood samples drawn at baseline, one month, and six months were profiled across three androgen-producing routes: the classical pathway, running from DHEA through androstenedione to testosterone and dihydrotestosterone; the 11-oxygenated pathway, producing adrenal androgens such as 11-ketotestosterone; and the little-known backdoor pathway, which bypasses testosterone to generate potent dihydrotestosterone metabolites like 5α-dihydroprogesterone and 3α-androstanediol. Progestogens, estrogens, and reproductive hormones including anti-Müllerian hormone, inhibin B, and sex hormone-binding globulin rounded out the panel.

The results tell a nuanced story about which hormones respond to which part of the dual blockade. In Group A, where both drugs acted from the start, classical androgens—testosterone, androstenedione, and their metabolites—fell sharply by one month and stayed low through six months, alongside marked drops in key progestogens and both estrone and estradiol. The free androgen index, a marker of bioavailable androgen, declined progressively. Crucially, the 11-oxygenated androgens, which are largely adrenal in origin, remained essentially stable, with only a modest and transient dip in 11-ketotestosterone at one month. That pattern, the authors argue, indicates that GnRHa effectively suppresses gonadal androgen output while adrenal steroidogenesis is left untouched.

Group B offered a natural comparison: in girls whose hypothalamic-pituitary-gonadal axis was already suppressed, adding letrozole produced far fewer hormonal ripples. Estradiol and estrone fell significantly, as did AMH and inhibin B—markers of ovarian follicular activity—but most androgens and progestogens held steady. A modest rise in two upstream precursors, pregnenolone and 17-hydroxydihydroprogesterone, appeared without any corresponding increase in downstream androgens, possibly reflecting mild accumulation of substrates blocked from aromatizing. Across both groups, no girl developed clinical or biochemical hyperandrogenism: none showed hirsutism by the modified Ferriman-Gallwey score, and none developed moderate-to-severe acne.

The safety signal extended beyond androgens. No letrozole-related adverse events—liver dysfunction, rash, or gastrointestinal symptoms—were recorded during the six-month window. Bone age, assessed by hand-wrist radiographs, advanced by a mean of 0.30 years in Group A and 0.23 years in Group B over six months, both slower than the expected 0.5-year chronological progression. That slowing is exactly what dual estrogen suppression should produce at the growth plate, though the authors caution that whether it ultimately translates into taller adults can only be answered with longer follow-up. The AMH and inhibin B declines mirror findings from standard GnRHa therapy and are considered reversible after treatment stops.

The findings build on, and extend, earlier work. The Greek GAIL study showed in 2016 that anastrozole combined with leuprorelin improved predicted adult height in early-maturing girls without testosterone abnormalities or bone density problems, but it did not perform comprehensive steroid profiling. Data from postmenopausal women on letrozole, whose estrogen physiology resembles that of GnRHa-suppressed girls, show estradiol reductions of 75 to 95 percent with minimal effects on adrenal steroids—and androgen-related side effects have been reported only with the steroidal inhibitor exemestane, not with letrozole or anastrozole. In boys, letrozole monotherapy is known to cause testosterone surges through gonadotropin rebound, but the new data confirm that GnRHa counteracts that mechanism when the two are combined in girls.

The study’s authors and outside observers alike stress the limits of the evidence. With 13 and 15 participants per group, a single center, no control arm, non-randomized group assignment, and only six months of observation, the results are preliminary rather than practice-changing. Gonadotropin levels were not measured in parallel, leaving some ambiguity about hypothalamic-pituitary dynamics, and inter-laboratory variability in LC-MS/MS assays complicates comparisons across studies. Because both drugs suppress estrogen signaling, the authors call for long-term monitoring of bone mineral density and growth. Still, within those boundaries, the study delivers what the field has lacked: a steroid-wide map showing that combined GnRHa and letrozole suppresses gonadal estrogens and androgens, spares the adrenal axis, and—at least over six months—does not push girls into androgen excess. Larger, longer trials will now be needed to determine whether this dual blockade can reliably bank centimeters of adult height without trading away long-term endocrine health.

Subject of Research: Endocrine effects of combined GnRHa and letrozole therapy on serum steroid profiles in girls with advanced bone age

Article Title: Effects of combined GnRHa and letrozole on serum steroid profiles in girls with advanced bone age

Article References: Zhang, X., Zhang, Y., Xing, Y., Yang, W., Qin, Y., Gao, X., Kong, X., Cai, S., Xue, G., Fan, X., Chen, M., Liu, Y., Chen, B., Yan, X., & Zhang, H. (2026). Effects of combined GnRHa and letrozole on serum steroid profiles in girls with advanced bone age. Frontiers in Endocrinology, 17, Article 1984633. https://doi.org/10.3389/fendo.2026.1984633

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1984633

Keywords: puberty, advanced bone age, GnRHa, letrozole, aromatase inhibitor, steroid hormones, LC-MS/MS, hyperandrogenism, rapidly progressive puberty, pediatric endocrinology, predicted adult height, bone age

The follicular fluid that bathes a developing egg is far more than a passive medium. It is a carefully balanced soup of sugars, amino acids, lipids, and signaling molecules that the oocyte and its surrounding cumulus cells draw upon as they grow, acquire energy, and prepare for the extraordinary demands of fertilization and early embryonic development. Any chemical imbalance in this niche can ripple directly into the quality of the egg released or retrieved during in vitro fertilization. This is why the new study focused squarely on follicular fluid rather than blood: blood reflects whole-body metabolism, but follicular fluid captures the immediate microenvironment in which the oocyte actually lives. Sampling this fluid from patients undergoing IVF-ET procedures offers a rare window into the biology of the egg at the moment it matters most.

The technical approach was deliberately comprehensive. The researchers used ultra-high-performance liquid chromatography coupled with mass spectrometry to profile the metabolome without preconceptions about which molecules might be altered, then followed up with a targeted lipidomics platform designed to precisely quantify individual lipid species. Multivariate statistical tools, including principal component analysis and orthogonal partial least-squares discriminant analysis, separated the PCOS samples from controls, while univariate tests identified individual molecules that differed significantly between the groups. The team then layered on functional enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes, correlation analysis against clinical parameters such as body mass index, luteinizing hormone, anti-Müllerian hormone, and antral follicle count, and finally logistic regression and receiver operating characteristic modeling to test whether the altered molecules could serve as diagnostic biomarkers.

The headline finding is a striking pattern the authors describe as triglyceride accumulation alongside phospholipid depletion. In the follicular fluid of PCOS patients, lysophospholipids and glycerophospholipids—the workhorse fats of cellular membranes—were widely downregulated, while certain long-chain triglycerides selectively accumulated. Crucially, this redistribution was not random. The shifts showed structural selectivity based on carbon chain length and degree of unsaturation, meaning that specific lipid species with particular architectures were preferentially affected. Because phospholipids form the membranes of the oocyte and its supporting cells, and because membrane fluidity depends heavily on the fatty acid composition of those phospholipids, their depletion could compromise the structural and functional integrity of the egg itself. Meanwhile, the buildup of storage triglycerides suggests a shift in how follicular cells handle energy, hoarding fat in storage form rather than deploying it in membrane-building and signaling roles.

Beyond lipids, the metabolomic screen uncovered disturbances in several other biologically meaningful classes. Branched-chain amino acids, specifically D-leucine and L-valine, were elevated in PCOS follicular fluid. Elevated branched-chain amino acids are a well-recognized signature of insulin resistance, a condition that affects a large proportion of PCOS patients even when they are lean, and their accumulation in the follicular niche suggests that the metabolic derangements seen systemically in PCOS penetrate all the way to the egg’s doorstep. Excess branched-chain amino acids can also perturb the balance of other amino acid pools and generate metabolic byproducts that stress developing cells, adding another layer of potential harm to oocyte quality.

The study also documented a meaningful imbalance in steroid hormone metabolites within the follicular fluid. Progesterone, the hormone that normally rises to support ovulation and prepare the reproductive tract for a potential pregnancy, was reduced in PCOS samples, while 17α-estradiol, a less common estrogenic compound, was elevated. Steroid hormones are the master chemical communicators of the follicle, coordinating the final maturation of the egg, the timing of its release, and the receptivity of surrounding tissues. A shift in their relative proportions could therefore disrupt the finely choreographed sequence of events that culminates in a fertilizable oocyte, offering a chemical explanation for the ovulatory dysfunction that defines the syndrome.

Perhaps the most unexpected finding involved one-carbon metabolism and related pathways. The researchers observed significant depletion of tetrahydropteridine, cytosine, and uridine in PCOS follicular fluid. Tetrahydropteridine, in its biologically active form tetrahydrobiopterin, is an essential cofactor for enzymes that produce nitric oxide and neurotransmitters and is intimately linked to folate-dependent one-carbon metabolism, which supplies the methyl groups needed for DNA synthesis and epigenetic regulation. Cytosine and uridine are fundamental building blocks of RNA and DNA. Their depletion points to an impairment of the nucleotide supply and methylation machinery inside the follicular microenvironment, processes that are especially critical during the final stages of oocyte maturation, when the egg must stockpile the molecular machinery for the first rounds of embryonic cell division before its own genome is even activated.

When the metabolomic and lipidomic datasets were integrated, three core dysregulated networks emerged: glycerophospholipid metabolism, steroid hormone biosynthesis, and insulin resistance signaling. This convergence is significant because it ties together threads that are usually studied in isolation. The membrane lipid depletion connects to the steroid hormone imbalance, since steroidogenic enzymes operate within membranes whose lipid composition influences their function, and both connect to insulin resistance, which is known to drive excess ovarian androgen production and alter lipid handling throughout the body. The integrated analysis thus reframes PCOS as a polyendocrine metabolic disorder of the ovary, in which a single web of interconnected biochemical pathways links the metabolic syndrome-like features of the disease to its reproductive consequences at the level of the individual egg.

The diagnostic implications are equally compelling. Using logistic regression and ROC analysis, the team evaluated whether panels of the altered molecules could distinguish PCOS patients from controls, and the results point toward promising multi-marker panels for clinical auxiliary diagnosis. Current PCOS diagnosis relies on clinical criteria—irregular ovulation, biochemical or clinical signs of excess androgen, and the ultrasound appearance of polycystic ovaries—which can be ambiguous, particularly in adolescents or in patients whose presentations overlap with other conditions. A molecular signature drawn from follicular fluid, or potentially from more accessible compartments if the same disturbances are mirrored in blood, could one day provide an objective biochemical complement to these criteria, and might even help stratify patients by the specific metabolic mechanisms driving their disease.

The study’s limitations are those inherent to its design: the sample size of 30 patients per group is modest, the cross-sectional design captures a single moment in time, and follicular fluid can only be obtained from women already undergoing assisted reproduction, which may introduce selection effects. Validation in larger and more diverse cohorts, and longitudinal studies tracking whether these molecular signatures predict actual embryo implantation and live birth outcomes, will be essential next steps. Nevertheless, the comprehensive molecular map produced by this research offers a concrete mechanistic foundation for a question that has long frustrated reproductive medicine: why do eggs from women with PCOS so often develop poorly? The answer, it now appears, lies in a follicular microenvironment starved of membrane-building phospholipids, flooded with storage fat and branched-chain amino acids, shortchanged on nucleotide precursors and methylation cofactors, and awash in the wrong balance of steroid hormones—a chemical storm that the developing egg must weather before it ever has a chance to become an embryo.

Subject of Research: Metabolic and lipidomic dysregulation of the follicular fluid microenvironment in polycystic ovary syndrome

Article Title: Integrated metabolomic and targeted lipidomic profiling reveals systemic metabolic dysregulation in the follicular microenvironment of polycystic ovary syndrome

Article References: Yue, J., Tian, D., Yue, Y., Qi, X., Yan, L., Liu, Q., & Zhao, Y. (2026). Integrated metabolomic and targeted lipidomic profiling reveals systemic metabolic dysregulation in the follicular microenvironment of polycystic ovary syndrome. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02287-4

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02287-4

Keywords: PCOS, follicular fluid, metabolomics, lipidomics, oocyte quality, phospholipids, triglycerides, branched-chain amino acids, insulin resistance, steroid hormones, biomarkers, fertility